StocksMedium•5 November 2026•
1 min read
Arcus Biosciences Reports Q3 Loss of $1 Per Share, Missing Estimates
Key Facts
1Arcus Biosciences reported a quarterly loss of $1 per share, wider than the Zacks Consensus Estimate of a $0.92 loss.
2The current quarter's results represent an improvement compared to a loss of $1.27 per share a year ago.
Arcus Biosciences reported a quarterly loss of $1 per share for the third quarter of 2026. Zacks reported that the results were wider than the $0.92 loss per share expected by analysts, with the company also missing revenue expectations.
The current quarter's performance represents an improvement over the loss of $1.27 per share recorded a year ago according to Zacks. RCUS closed at $19.31 on November 4, 2026, having traded between a low of $18.6 and a high of $19.63 during that session.